ライフサイエンスコーパス: relaxin

1 bit collagen deposition similar to native H2 relaxin.

2 ion and reduced contractility in response to relaxin.

3 distal actions of low circulating levels of relaxin.

4 pression of LGR7, the cognate receptor of H2 relaxin.

5 at perfectly matches the binding cassette of relaxin.

6 nancy and its use in defining the actions of relaxin.

7 GPCR135 and GPCR142 by its high affinity for relaxin.

8 ion of ML290 increased p-ERK1/2 responses to relaxin.

9 ndent activation of PPARgamma in response to relaxin.

10 NA diminished the regulation of PPARgamma by relaxin.

11 glucose production are corrected by chronic relaxin.

12 Relaxin-1 and its major receptor, Lgr7, mRNA are express

13 Small renal arteries isolated from relaxin-1 gene-deficient mice demonstrate enhanced myoge

14 chimeric peptides indicates the A-chain from relaxin-1, relaxin-2, insulin-like peptide (INSL)3, and

15 -h intravenous infusion of placebo (n=62) or relaxin 10 microg/kg (n=40), 30 microg/kg (n=43), 100 mi

16 ere assessed in the placebo group, 40 in the relaxin 10 microg/kg per day group, 42 in the relaxin 30

17 (dcSSc) were administered recombinant human relaxin (10 microg/kg/day or 25 microg/kg/day) or placeb

18 elaxin 30 microg/kg per day group, 37 in the relaxin 100 microg/kg per day group, and 49 in the relax

19 ive rats (SHRs), and SHRs treated with human relaxin 2 for 14 d (4 mug/h; n=8/group) and studied usin

20 or renal failure at day 60 was reduced with relaxin (2.6% [95% CI 0.4-16.8] vs 17.2% [9.6-29.6]; p=0

21 The peptide hormone human relaxin-2 (H2-RLX) has emerged as a potential therapy fo

22 Recombinant human relaxin-2 (rhRLX) stimulated PI3K/Akt B-dependent NO pro

23 Recombinant human relaxin-2 (serelaxin), which has organ-protective action

24 imals treated with multiple IA injections of relaxin-2 compared with the untreated control and the sI

25 Recombinant human relaxin-2 down-regulates type I collagen and alpha smoot

26 ein, the naturally occurring peptide hormone relaxin-2 is administered for the treatment of adhesive

27 As these findings show, local delivery of relaxin-2 is an innovative treatment of shoulder arthrof

28 er, been hampered by cross-activation of the relaxin-2 receptor, RXFP1, in the brain.

29 hrofibrosis, multiple IA injections of human relaxin-2 significantly improve ROM, returning it to bas

30 A (sIA) or multiple i.v. (mIV) injections of relaxin-2 with which the ROM remains constrained.

31 Serelaxin (recombinant human relaxin-2) is a peptide molecule with anti-fibrotic and

32 Serelaxin is a recombinant form of human relaxin-2, a vasodilator hormone that contributes to car

33 ptides indicates the A-chain from relaxin-1, relaxin-2, insulin-like peptide (INSL)3, and INSL6 does

34 m of the naturally occurring peptide hormone relaxin-2, is a pleiotropic vasodilating hormone that ha

35 Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many bio

36 dy, serelaxin, the recombinant form of human relaxin-2, reduced post-discharge mortality at 180 days

37 cy of serelaxin, a recombinant form of human relaxin-2.

38 stemic and intraarticular (IA) half-lives of relaxin-2: 0.96 h and 0.62 h, respectively.

39 n 100 microg/kg per day group, and 49 in the relaxin 250 microg/kg per day group.

40 tudy undertook to develop analogues of human relaxin-3 (H3 relaxin) that can selectively bind and act

41 he regulation of feeding behavior, including relaxin-3 (RLN3), which stimulates food intake in rats t

42 one (GnRH), a G-protein-coupled receptor for relaxin-3 (RXFP3) and a functional cyclic nucleotide-gat

43 In contrast, substitution of the relaxin-3 A-chain with the A-chain from INSL5 results in

44 Because relaxin-3 also activates the relaxin receptor (LGR7), wh

45 the study of the physiological functions of relaxin-3 and GPCR135 in vivo.

46 Both relaxin-3 and its receptor (GPCR135) are expressed predo

47 gonist, R3(BDelta23-27)R/I5, consists of the relaxin-3 B-chain with a replacement of Gly23 to Arg, a

48 INSL5 inhibits (125)I-relaxin-3 binding to GPCR135 with a low potency (K(i) =

49 Relaxin-3 colocalized with synaptophysin in nerve termin

50 Dense relaxin-3 fiber plexuses were observed in regions of med

51 Relaxin-3 fibers were also observed in the septofimbrial

52 In lateral septum (LS), relaxin-3 fibers were concentrated in the ventrolateral

53 s, we have characterized the distribution of relaxin-3 fibers/terminals in relation to different sept

54 eptides that consist of the B-chain of human relaxin-3 in combination with various A-chains from othe

55 Relaxin-3 is a neuropeptide that is implicated in the re

56 Recent studies have shown that relaxin-3 is involved in the regulation of stress and fe

57 In situ hybridization showed that relaxin-3 mRNA is predominantly expressed in the dorsome

58 relaxin-3, and pharmacological modulation of relaxin-3 receptors in medial septum alters hippocampal

59 not change the pharmacological properties of relaxin-3 significantly.

60 ojected to hippocampus, and contacts between relaxin-3 terminals and calbindin- and calretinin-positi

61 Human INSL5 displaces the binding of (125)I-relaxin-3 to GPCR142 with a high affinity (K(i) = 1.5 nM

62 f a very hydrophobic peptide (the A-chain of relaxin-3) with a very hydrophilic peptide (the A-chain

63 neurons express the relaxin-family peptide, relaxin-3, and pharmacological modulation of relaxin-3 r

64 eptor for the highly conserved neuropeptide, relaxin-3, decreased self-administration of alcohol in a

65 Relaxin-3, the most recently identified member of relaxi

66 he regulation of feeding behavior, including relaxin-3, which acts via the relaxin-family peptide-3 r

67 companying article, we present the case that relaxin-3, which has previously been shown to bind to th

68 However, unlike relaxin-3, which is also a potent agonist for GPCR135 an

69 In the medial septum, we observed relaxin-3-immunoreactive contacts with ChAT-, PV-, and g

70 behaves as an agonist for GPCR142 similar to relaxin-3.

71 The mechanisms underlying the involvement of relaxin-3/GPCR135 in the regulation of stress, feeding,

72 further delineation of the functions of the relaxin-3/GPCR135 system.

73 A-chain from INSL5), the radiolabeled (125)I-relaxin-3/INSL5 chimera is a suitable ligand (high-affin

74 The relaxin-3/INSL5 chimeric peptide is a potential tool to

75 n of a selective GPCR135 agonist (a chimeric relaxin-3/INSL5 peptide designated R3/I5).

76 model of binge-eating, we demonstrated that relaxin-3/RXFP3 signaling in the hypothalamic paraventri

77 These data suggest that relaxin-3/RXFP3 signaling regulates alcohol intake and r

78 Dyspnoea improved with relaxin 30 microg/kg compared with placebo, as assessed

79 elaxin 10 microg/kg per day group, 42 in the relaxin 30 microg/kg per day group, 37 in the relaxin 10

80 Nonpregnant rats were treated with relaxin (4 mug/h, osmotic minipump), relaxin plus PPARga

81 sting inward remodeling that was reversed by relaxin (56+/-4 mum, P<0.05).

82 Relaxin, a peptide hormone produced during pregnancy, is

83 The physiological effects of relaxin, a pleiotropic hormone with therapeutic potentia

84 Previously, we have shown that relaxin activates PPARgamma transcriptional activity in

85 These results suggest that relaxin activates the cAMP/PKA and p38 MAPK pathways to

86 Relaxin activation of its receptor RXFP1 triggers multip

87 In the injured muscle, relaxin administration promoted the activation of Pax7-p

88 Relaxin also increased PA distensibility in SHRs (34+/-2

89 Relaxin, an emerging pharmaceutical treatment for acute

90 Relaxin, an insulin-like hormone, suppresses atrial fibr

91 osophila insulin-like peptide 8 (Dilp8) as a relaxin and insulin-like molecule secreted from growing

92 athway in the renal vasodilatory response to relaxin and pregnancy.

93 er there is local expression and function of relaxin and relaxin receptor in arteries of nonpregnant

94 in that the secondary interaction between H2 relaxin and RXFP1 is not driven by any single amino acid

95 vercome the many challenges of investigating relaxin and the LDLa module interactions with the ELs, w

96 interaction that involves the A-chain of H2 relaxin and transmembrane exoloops of the receptors.

97 ndings demonstrate a close interplay between relaxin and Wnt-signaling resulting in myocardial remode

98 The discontinuation of both doses of relaxin at week 24 led to statistically significant decl

99 viously shown that a potential limitation to relaxin-based IPF therapy is decreased expression of a r

100 n would be predicted to be most sensitive to relaxin-based therapies.

101 90 did not directly compete with orthosteric relaxin binding and did not affect binding kinetics, but

102 model explains the exquisite sensitivity of relaxin binding avidity to minute changes in the disposi

103 nown about the molecular mechanisms by which relaxin binding results in receptor activation.

104 utated in RXFP1, and changes in function and relaxin binding were assessed alongside the RXFP1 agonis

105 rich G-protein-coupled receptor 7 supports a relaxin-binding group of amino acids that perfectly matc

106 H2 relaxin binds to the leucine-rich repeats of RXFP1 and R

107 operties to support further investigation of relaxin biology and animal efficacy studies of the thera

108 In isolated fibroblasts, relaxin blocked TGFbeta-induced collagen elevation in a

109 d no effect on increased distensibility with relaxin, but caused outward hypertrophic remodeling of P

110 a reporter gene assay to demonstrate that H2 relaxin can induce the expression of prostate-specific a

111 e have previously demonstrated that human H2-relaxin can mediate androgen-independent growth of LNCaP

112 is to elucidate the mechanism(s) by which H2-relaxin causes activation of the AR pathway.

113 Growing evidence indicates that circulating relaxin causes vasodilatation and increases in arterial

114 The ovarian peptide hormone, relaxin, circulates during pregnancy, contributing to pr

115 f the secondary structure to the extent that relaxin cross-reacts with the LGR8, the RLF receptor.

116 These results suggest that relaxin crosses the BBB and activates MMP-2 in brain cor

117 The binding cassette of relaxin cuts at an angle of approximately 45 degrees acr

118 In addition, relaxin decreases endometrial levels of matrix metallopr

119 rthermore, nonreplicating viruses expressing relaxin did not increase metastases, suggesting that hig

120 Taken together, these results indicate that relaxin effects BMDEC function through the RXFP1 recepto

121 IR-99021 (a GSK3beta inhibitor) mimicked the relaxin effects.

122 Thus, we hypothesized that relaxin enhances BMDEC NO production, circulating number

123 Results demonstrate that relaxin exerts dramatic uterine effects including pronou

124 throughout the tumor when compared with non-relaxin-expressing, Ad5-based viruses.

125 ccupied by STAT3 on day 6 of pregnancy, when relaxin expression is minimal; on day 15, when expressio

126 Downregulation of H2 relaxin expression results in significant inhibition of

127 ith STAT5 playing a role in the induction of relaxin expression.

128 Analyses of relaxin family genes on syntenic regions of model tetrap

129 acterization of contemporary and resurrected relaxin family hormones, we show that derivation of INSL

130 that the A-chains among some of the insulin/relaxin family members are pharmacologically exchangeabl

131 It interacts with two of the relaxin family peptide (RXFP) receptors.

132 al administration of peptide antagonists for relaxin family peptide 3 receptor (RXFP3), the cognate r

133 tment for acute heart failure, activates the relaxin family peptide receptor (RXFP1), which is a clas

134 d via its cognate G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), has emerged a

135 tions through the G protein-coupled receptor relaxin family peptide receptor 1 (RXFP1), little is kno

136 nalosome, that couples the relaxin receptor, relaxin family peptide receptor 1 (RXFP1), to cAMP follo

137 cule agonists of the human relaxin receptor, relaxin family peptide receptor 1 (RXFP1).

138 linkage disequilibrium on chromosome 13 near relaxin family peptide receptor 2 (RXFP2) were associate

139 Relaxin family peptide receptor 3 (RXFP3) signaling in t

140 and vasoprotective properties that binds to relaxin family peptide receptor-1 (RXFP1) and has been s

141 gnate G-protein coupled receptor for H2-RLX (relaxin family peptide receptor-1 (RXFP1)).

142 , a member of the highly conserved family of relaxin family peptide receptors (RXFPs), mediates the c

143 ligand-receptor pairs, relationships between relaxin family peptides and leucine-rich repeat-containi

144 ies demonstrated that two of the seven human relaxin family peptides, relaxin H2 (RLN2) and INSL3, si

145 These neurons express the relaxin-family peptide, relaxin-3, and pharmacological m

146 ior, including relaxin-3, which acts via the relaxin-family peptide-3 receptor (RXFP3).

147 intake in rats through the activation of the relaxin-family peptide-3 receptor (RXFP3).

148 t drivers of the affinity and activity of H2 relaxin for RXFP2 with additional minor contributions fr

149 t for 13 weeks and continuously treated with relaxin for the final 3 weeks of the diet exhibited decr

150 The Relaxin for the Treatment of Acute Heart Failure (RELAX-

151 In the RELAX-AHF (Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure) study,

152 Expressing relaxin from Ad5/Ad35 fiber chimeric adenoviruses may pr

153 g that oncolytic adenoviruses expressing the relaxin gene and containing an Ad5/Ad35 chimeric fiber s

154 g/day and 25 microg/kg/day recombinant human relaxin, given for 24 weeks in patients with stable, dif

155 ital capacity decreased significantly in the relaxin groups.

156 of the seven human relaxin family peptides, relaxin H2 (RLN2) and INSL3, signal exclusively through

157 The polypeptide hormone relaxin has been proven to be effective in promoting bot

158 is directly (bosentan, interferon gamma, and relaxin) have been disappointing but new strategies agai

159 The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX

160 on in various mammalian species, the role of relaxin in human reproduction is poorly understood, larg

161 er, the molecular and cellular mechanisms of relaxin in regulating both myogenic cell differentiation

162 documented importance of the protein hormone relaxin in reproduction in various mammalian species, th

163 ese results revealed the multiple effects of relaxin in systematically improving muscle healing as we

164 ty are consistent with a significant role of relaxin in the establishment and/or maintenance of early

165 These studies show the potential of relaxin in the treatment of diet-induced insulin resista

166 Furthermore, relaxin increased the levels of connexin43, Wnt1, and cy

167 Relaxin increased the mRNA and protein levels of the coa

168 We show that the matrix-modifying hormone relaxin increased tumor-associated fibroblast (TAF) inte

169 re not detected in cerebral vasculature, but relaxin increased vascular endothelial growth factor (VE

170 The endogenous hormone relaxin increases vascular reactivity and angiogenesis.

171 -specific small interfering RNA inhibited H2-relaxin-induced AR activity.

172 GW9662 also prevented relaxin-induced changes in PPARgamma target gene express

173 to be involved in remodeling of PAs, but not relaxin-induced increased distensibility.

174 We demonstrate that acute relaxin infusion in lean C57BL/6J mice enhances skeletal

175 Exogenous relaxin inhibits MLC(20) phosphorylation and bleomycin-i

176 e 5 (INSL5) is a peptide that belongs to the relaxin/insulin family, and its receptor has not been id

177 in-3, the most recently identified member of relaxin/insulin family, is an agonist for leucine-rich r

178 h various A-chains from other members of the relaxin/insulin family.

179 in-like peptide 3 (INSL3) is a member of the relaxin/insulin superfamily and is expressed in testicul

180 efficient production platform for expressing relaxin/insulin superfamily peptides.

181 decreased expression of a relaxin receptor, relaxin/insulin-like family peptide receptor 1 (RXFP1),

182 icacy studies of the therapeutic benefits of relaxin/insulin-like family peptide receptor 1 activatio

183 ent the first small-molecule series of human relaxin/insulin-like family peptide receptor 1 agonists.

184 linergic receptor, muscarinic 2), and RXFP1 (relaxin/insulin-like family peptide receptor 1).

185 One lying upstream of the relaxin/insulin-like family peptide receptor 2 ( RXP2) (

186 d reduction in expression of INSL3 receptor, relaxin/insulin-like family peptide receptor 2 (RXFP2).

187 function in adult males via interaction with relaxin/insulin-like family peptide receptor 2 (RXFP2).

188 In BMDECs isolated from relaxin/insulin-like family peptide receptor 2 gene (Rxf

189 candidate genes, such as insulin-like 3 and relaxin/insulin-like family peptide receptor 2, in cases

190 Relaxin intervention improves endothelial-dependent vasc

191 Relaxin intervention reverses the accumulation of collag

192 tudies identify a novel antifibrotic role of relaxin involving the inhibition of the contractile phen

193 Relaxin is a 6 kDa protein hormone produced by the corpu

194 Relaxin is a hormone that has been considered as a poten

195 Relaxin is a natural human peptide that affects multiple

196 To conclude, relaxin is a novel regulator of BMDECs number and functi

197 Relaxin is a peptide hormone that mediates antifibrotic

198 vessel disease (SVD), and determined whether relaxin is a treatment for SVD during hypertension.

199 dition, our previous study demonstrated that relaxin is beneficial to skeletal muscle healing by both

200 Thus, relaxin is bound by synchronized chelation of two argini

201 The hormone relaxin is considered a potential therapy for idiopathic

202 Relaxin is contraindicated due to inefficacy and severe

203 Human gene-2 (H2) relaxin is currently in Phase III clinical trials for th

204 Thus, we hypothesized that relaxin is involved in the selective outward remodeling

205 ain, the sharply defined binding cassette of relaxin is not present in RLF.

206 H2 relaxin is overexpressed in the LNCaP-R273H subline.

207 However, the use of relaxin is problematic because of a short half-life.

208 In addition, we demonstrate that H2 relaxin is responsible for facilitating p53(R273H)-media

209 The peptide hormone relaxin is showing potential as a treatment for acute he

210 If relaxin is used therapeutically for any conditions other

211 and bleomycin-induced lung fibrosis in both relaxin knockout and wild-type mice.

212 Compared with wild-type mice, relaxin knockout mice express higher lung levels of phos

213 ivation interaction of RXFP1 and RXFP2 by H2 relaxin, leading to a potent and RXFP1-selective analog,

214 , these findings reveal an arterial-derived, relaxin ligand-receptor system that acts locally to regu

215 The relaxin-like actions of CGEN25009 were abrogated by RXFP

216 The relaxin-like effects of CGEN25009 in vitro are dependent

217 lasts exhibited decreased sensitivity to the relaxin-like effects of CGEN25009.

218 The relaxin-like factor (RLF) also named insulin-like 3 (INS

219 uggest that the receptor-binding site of the relaxin-like factor (RLF) is located in the flexible C-t

220 The relaxin-like factor (RLF) is thought to be responsible f

221 Analogous to insulin, the relaxin-like factor (RLF) must undergo a structural tran

222 The relaxin-like factor (RLF, also named INSL3) is a critica

223 vered the signal initiation structure of the relaxin-like factor and shown its function to be indepen

224 s small protein permits one to study how the relaxin-like factor initiates the signal on the receptor

225 We tested CGEN25009, a relaxin-like peptide, in lung fibroblasts and in bleomyc

226 t targeting myofibroblast contractility with relaxin-like peptides may be of therapeutic benefit in t

227 tural and sexual selection at a single gene, relaxin-like receptor 2 (RXFP2).

228 In summary, the data show that relaxin may play a role in rearranging matrix components

229 Relaxin-mediated activation of RXFP1 requires multiple c

230 ponents of the Wnt pathway can facilitate H2-relaxin-mediated activation of the AR pathway.

231 t pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3beta an

232 Although it is known that relaxin mediates its actions through the G protein-coupl

233 lve parallel from the B-chain alpha-helix of relaxin, neutralize the charge repulsion of the juxta-po

234 ogenic therapeutic properties of recombinant relaxin peptide hormone have been investigated in severa

235 The beneficial effects of relaxin peptide treatment were demonstrated in clinicall

236 Relaxin peptides are important hormones for the regulati

237 ed with relaxin (4 mug/h, osmotic minipump), relaxin plus PPARgamma inhibitor GW9662 (10 mg/kg/d), or

238 Expression of relaxin precursor mRNA in rats is sharply induced after

239 These results suggest that relaxin produced during pregnancy may be partly responsi

240 Results showed that relaxin promoted myogenic differentiation, migration, an

241 strate that p53(R273H) binds directly to the relaxin promoter, further confirming a role for H2 relax

242 Relaxin provides a novel therapeutic approach targeting

243 eptor, formyl peptide receptor-2 (FPR2), the relaxin receptor (LGR7), G-proteins (Galpha(q/11/o/13)),

244 Because relaxin-3 also activates the relaxin receptor (LGR7), which is also expressed in the

245 local expression and function of relaxin and relaxin receptor in arteries of nonpregnant females and

246 ich has previously been shown to bind to the relaxin receptor LGR7, is most likely the endogenous lig

247 c effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis.

248 Activation of the relaxin receptor RXFP1 has been associated with improved

249 s indicate that the small molecules activate relaxin receptor through an allosteric site.

250 ly active GPCR signalosome, that couples the relaxin receptor, relaxin family peptide receptor 1 (RXF

251 ntified small molecule agonists of the human relaxin receptor, relaxin family peptide receptor 1 (RXF

252 sed IPF therapy is decreased expression of a relaxin receptor, relaxin/insulin-like family peptide re

253 Lgr3 is a member of the relaxin-receptor family and a receptor for Dilp8, necess

254 Relaxin receptors (RXFP1/2) were not detected in cerebra

255 zation of the signaling pathway reveals that relaxin regulates MLC(20) dephosphorylation and lung myo

256 cells stably expressing RXFP1, we found that relaxin regulation of PPARgamma activity requires accumu

257 Administration of recombinant human relaxin (rhRLX) to conscious, chronically instrumented r

258 The relaxin (RLN) and insulin-like (INSL) gene family is a g

259 ign of triple combination regimen, including relaxin (RLN), FOLFOX (combination of 5-fluorouracil, le

260 t-term administration of the peptide hormone relaxin (RLN).

261 Here, we discover intra-hepatic scale-up of relaxin (RLN, an anti-fibrotic peptide) in response to f

262 H2-relaxin (RLN2) is a two-chain peptide hormone structural

263 w that inducible, intratumoral expression of relaxin (Rlx) either by transplanting tumor cells that c

264 prehensive evidence that the ovarian hormone relaxin (RLX) is responsible.

265 rcome the poor delivery of oAd into hMSCs, a relaxin (RLX)-expressing oncolytic Ad (oAd/RLX), which d

266 tools to study the physiological roles of H3 relaxin/RXFP3 systems in the brain and important leads f

267 We assessed the dose response of relaxin's effect on symptom relief, other clinical outco

268 RLF and relaxin share features of the secondary structure to the

269 were explored to assess whether intravenous relaxin should be pursued in larger studies of acute hea

270 n promoter, further confirming a role for H2 relaxin signaling in p53(R273H)-mediated AI CaP.

271 Relaxin significantly inhibits endometrial levels of est

272 Moreover, relaxin similarly promoted muscle healing in mice with a

273 The findings that relaxin stimulates new blood vessel formation and increa

274 During pregnancy, relaxin stimulates nitric oxide (NO)-dependent renal vas

275 Activated CREB was required for relaxin stimulation of PPARgamma activity, while there w

276 omized controlled trial of recombinant human relaxin suggested that a dosage of 25 microg/kg/day was

277 ry mechanism for the extremely low levels of relaxin that circulate.

278 to develop analogues of human relaxin-3 (H3 relaxin) that can selectively bind and activate its rece

279 hypertension) in 7 patients who had received relaxin therapy but in none who had received placebo.

280 nd primary human myoblasts were treated with relaxin to investigate its potential effect in vitro; re

281 Addition of H2-relaxin to LNCaP cells resulted in increased phosphoryla

282 th, whereas addition of recombinant human H2 relaxin to parental LNCaP promotes AI growth.

283 Relaxin treatment increased serum relaxin to the level of pregnancy (54 ng/ml) and increas

284 d inflammatory reaction was repressed in the relaxin-treated injured muscle.

285 enic reactivity of small renal arteries from relaxin-treated nonpregnant and midterm pregnant rats.

286 Length of stay was 10.2 days (SD 6.1) for relaxin-treated patients versus 12.0 days (7.3) for thos

287 ed renal vasodilation and hyperfiltration in relaxin-treated rats.

288 Relaxin treatment increased serum relaxin to the level o

289 Here we show that relaxin treatment of aged rats reverses pathological ele

290 21.0 in the D-Pen Trial cohort, 27.3 in the Relaxin Trial cohort, and 26.1 in the Collagen Trial coh

291 ), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine type I collagen versus p

292 In isolated adult ventricular myocytes, relaxin upregulated Nav1.5 (EC(50) = 1.3 nM) by a mechan

293 nicillamine (D-Pen Trial), recombinant human relaxin versus placebo (Relaxin Trial), and oral bovine

294 o investigate its potential effect in vitro; relaxin was also injected intramuscularly into the injur

295 lure and normal-to-increased blood pressure, relaxin was associated with favourable relief of dyspnoe

296 In addition, relaxin was associated with serious renal adverse events

297 Relaxin was detected in cerebrospinal fluid (110+/-30 pg

298 Recombinant relaxin was not significantly better than placebo in imp

299 dies for rat and mouse Lgr7 receptor and rat relaxin, we also identified protein expression in arteri

300 es, suggesting that high level expression of relaxin will not enhance metastatic spread of tumors.